- Home
- ANGH vs COEP Comparison
ANGH vs COEP Comparison
Compare ANGH & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- COEP
- Stock Information
- Founded
- ANGH 2012
- COEP 2017
- Country
- ANGH United Arab Emirates
- COEP United States
- Employees
- ANGH N/A
- COEP N/A
- Industry
- ANGH Telecommunications Equipment
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANGH Consumer Discretionary
- COEP Health Care
- Exchange
- ANGH Nasdaq
- COEP Nasdaq
- Market Cap
- ANGH 32.1M
- COEP 27.4M
- IPO Year
- ANGH N/A
- COEP N/A
- Fundamental
- Price
- ANGH $0.45
- COEP $11.63
- Analyst Decision
- ANGH
- COEP
- Analyst Count
- ANGH 0
- COEP 0
- Target Price
- ANGH N/A
- COEP N/A
- AVG Volume (30 Days)
- ANGH 195.6K
- COEP 52.7K
- Earning Date
- ANGH 08-05-2025
- COEP 08-15-2025
- Dividend Yield
- ANGH N/A
- COEP N/A
- EPS Growth
- ANGH N/A
- COEP N/A
- EPS
- ANGH N/A
- COEP N/A
- Revenue
- ANGH $78,093,405.00
- COEP $62,874.00
- Revenue This Year
- ANGH N/A
- COEP N/A
- Revenue Next Year
- ANGH N/A
- COEP N/A
- P/E Ratio
- ANGH N/A
- COEP N/A
- Revenue Growth
- ANGH 88.72
- COEP N/A
- 52 Week Low
- ANGH $0.42
- COEP $2.31
- 52 Week High
- ANGH $1.01
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- ANGH 42.31
- COEP 66.85
- Support Level
- ANGH $0.44
- COEP $10.00
- Resistance Level
- ANGH $0.51
- COEP $11.70
- Average True Range (ATR)
- ANGH 0.05
- COEP 0.89
- MACD
- ANGH -0.00
- COEP 0.30
- Stochastic Oscillator
- ANGH 6.78
- COEP 76.97
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.